|
1）Kobori H, Nangaku M, Navar LG, et al. The intrarenal renin-angiotensin system: From physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007; 59: 251-87
|
|
|
|
2）Pohl M, Kaminski H, Castrop H, et al. Intrarenal renin angiotensin system revisited: Role of megalin-dependent endocytosis along the proximal nephron. J Biol Chem. 2010; 285: 41935-46
|
|
|
|
|
|
3）Matsusaka T, Niimura F, Shimizu A, et al. Liver angiotensinogen is the primary source of renal angiotensin II. J Am Soc Nephrol. 2012; 23: 1181-9
|
|
|
|
|
|
4）Herrera M, Sparks MA, Alfonso-Pecchio AR, et al. Lack of specificity of commercial antibodies leads to misidentification of angiotensin type 1 receptor protein. Hypertension. 2013; 61: 253-8
|
|
|
|
|
|
5）Jankowski V, Vanholder R, van der Giet M, et al. Mass-spectrometric identification of a novel angiotensin peptide in human plasma. Arterioscler Thromb Vasc Biol. 2007; 27: 297-302
|
|
|
|
|
|
6）Favaro S, Baggio B, Castellani A, et al. Urinary angiotensinogen loss in chronic proteinuric glomerulonephritis. Int Urol Nephrol. 1972; 4: 195-8
|
|
|
|
|
|
7）Nakano D, Kobori H, Burford JL, et al. Multiphoton imaging of the glomerular permeability of angiotensinogen. J Am Soc Nephrol. 2012; 23: 1847-56
|
|
|
|
|
|
8）Gonzalez-Villalobos RA, Janjoulia T, Fletcher NK, et al. The absence of intrarenal ace protects against hypertension. J Clin Invest. 2013; 123: 2011-23
|
|
|
|
|
|
9）Crowley SD, Gurley SB, Herrera MJ, et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A. 2006; 103: 17985-90
|
|
|
|
|
|
10）Verlander JW, Hong S, Pech V, et al. Angiotensin II acts through the angiotensin 1a receptor to upregulate pendrin. Am J Physiol Renal Physiol. 2011; 301: F1314-25
|
|
|
|
|
|
11）Cook JL, Re RN. Lessons from in vitro studies and a related intracellular angiotensin II transgenic mouse model. Am J Physiol Regul Integr Comp Physiol. 2012; 302: R482-93
|
|
|
|
|